Willow Biosciences Inc. (TSX:WLLW)
Canada
· Delayed Price · Currency is CAD 0.0350
-0.0050 (-12.50%)
May 22, 2025, 2:26 PM EDT
Willow Biosciences Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 6.37 | 4.66 | 1.17 | 0.82 | 0.13 | 0.01 | Upgrade
|
| Revenue Growth (YoY) | 571.23% | 297.78% | 42.75% | 517.29% | 1230.00% | 100.00% | Upgrade
|
| Cost of Revenue | 5.06 | 5.06 | 6.8 | 7.47 | 11.53 | - | Upgrade
|
| Gross Profit | 1.31 | -0.4 | -5.63 | -6.65 | -11.4 | 0.01 | Upgrade
|
| Selling, General & Admin | 3.31 | 3.5 | 5.6 | 7.64 | 6.9 | 5.47 | Upgrade
|
| Research & Development | 0 | - | - | - | - | 7.26 | Upgrade
|
| Operating Expenses | 4.46 | 5.19 | 7.85 | 11.75 | 11.8 | 16.86 | Upgrade
|
| Operating Income | -3.14 | -5.58 | -13.48 | -18.4 | -23.2 | -16.85 | Upgrade
|
| Interest Expense | -0.3 | -0.26 | -0.14 | -0.03 | -0.03 | -0.04 | Upgrade
|
| Interest & Investment Income | 0.07 | 0.07 | 0.27 | 0.3 | 0.41 | 0.16 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.01 | -0.01 | 0.3 | -0.01 | -0.05 | -0.02 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.77 | -0.54 | 0.02 | 3.76 | 16.8 | -11 | Upgrade
|
| EBT Excluding Unusual Items | -4.15 | -6.32 | -13.03 | -14.38 | -6.05 | -27.75 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | -0.38 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 0.14 | - | - | -0.09 | -0.08 | Upgrade
|
| Asset Writedown | - | - | - | - | - | -6.12 | Upgrade
|
| Pretax Income | -4.15 | -6.19 | -13.03 | -14.76 | -6.14 | -33.95 | Upgrade
|
| Income Tax Expense | 0 | 0 | -0.01 | 0.05 | - | - | Upgrade
|
| Net Income | -4.15 | -6.19 | -13.03 | -14.81 | -6.14 | -33.95 | Upgrade
|
| Net Income to Common | -4.15 | -6.19 | -13.03 | -14.81 | -6.14 | -33.95 | Upgrade
|
| Shares Outstanding (Basic) | 174 | 135 | 124 | 124 | 120 | 82 | Upgrade
|
| Shares Outstanding (Diluted) | 174 | 135 | 124 | 124 | 120 | 82 | Upgrade
|
| Shares Change (YoY) | 86.56% | 8.29% | 0.47% | 3.06% | 46.34% | 13.77% | Upgrade
|
| EPS (Basic) | -0.02 | -0.05 | -0.10 | -0.12 | -0.05 | -0.41 | Upgrade
|
| EPS (Diluted) | -0.02 | -0.05 | -0.10 | -0.12 | -0.05 | -0.41 | Upgrade
|
| Free Cash Flow | -2.03 | -3.74 | -11.59 | -14.54 | -19.9 | -13.73 | Upgrade
|
| Free Cash Flow Per Share | -0.01 | -0.03 | -0.09 | -0.12 | -0.17 | -0.17 | Upgrade
|
| Gross Margin | 20.61% | -8.47% | - | - | - | 100.00% | Upgrade
|
| Operating Margin | -49.33% | -119.71% | -1149.91% | -2241.17% | -17440.60% | -168460.00% | Upgrade
|
| Profit Margin | -65.12% | -132.75% | -1111.69% | -1804.38% | -4616.54% | -339460.00% | Upgrade
|
| Free Cash Flow Margin | -31.90% | -80.29% | -988.82% | -1771.26% | -14960.15% | -137320.00% | Upgrade
|
| EBITDA | -2.85 | -4.95 | -12.62 | -16.51 | -20.67 | -14.4 | Upgrade
|
| EBITDA Margin | -44.74% | -106.20% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 0.29 | 0.63 | 0.86 | 1.9 | 2.52 | 2.44 | Upgrade
|
| EBIT | -3.14 | -5.58 | -13.48 | -18.4 | -23.2 | -16.85 | Upgrade
|
| EBIT Margin | -49.33% | -119.71% | - | - | - | - | Upgrade
|
| Revenue as Reported | 6.37 | 4.66 | 1.17 | 0.82 | 0.13 | 0.01 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.